Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)

Overview

Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that is caused by cigarette smoking or by breathing in other lung irritants, including pollution, dust, or chemicals. The purpose of this study is to evaluate the effectiveness of zileuton, a medication that is used to control asthma symptoms, at reducing the length of a hospital stay for adults who are hospitalized for a COPD exacerbation, or worsening of COPD symptoms.

Full Title of Study: “Antileukotriene Therapy for COPD Exacerbations”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: December 2008

Detailed Description

COPD is a disease in which the lung airways are partly damaged and obstructed, making it difficult to breathe. COPD is the fourth leading cause of death in the United States. Symptoms include coughing, excess mucus production, shortness of breath, wheezing, and chest tightness. Treatment usually includes inhaled bronchodilator or steroid medications that work by relaxing the muscles around the lung airways and reducing inflammation. Zileuton, a medication that is used to prevent asthma symptoms, may be beneficial in treating people who experience COPD exacerbations. Zileuton works by blocking the formation of substances that cause inflammation, fluid retention, and constriction in the lungs. The purpose of this study is to evaluate the effectiveness of zileuton at reducing the length of a hospital stay for adults who are hospitalized for a COPD exacerbation. This study will enroll adults who are admitted to the hospital due to severe COPD symptoms. Participants will be randomly assigned to receive either zileuton or placebo four times a day for up to 14 days. While in the hospital, lung function testing and urine collection will occur. Study visits will occur at Days 14 and 30, and will include lung function testing, a medical history review, and a study drug adverse effects review.

Interventions

  • Drug: Zileuton
    • Zyflo tablets, 600 mg, 4 times a day
  • Drug: Placebo
    • Placebo 4 x daily

Arms, Groups and Cohorts

  • Active Comparator: Zileuton
    • Zileuton (Zyflo, 600 mg 4 times a day)
  • Placebo Comparator: Placebo
    • Placebo

Clinical Trial Outcome Measures

Primary Measures

  • Length of Hospital Stay
    • Time Frame: Measured at Day 30
    • Admission will begin at the time the subject has been admitted to an inpatient service. Length of Stay (LOS) will be recorded in days. The LOS will be based on the number of days spent in an acute medical ward or in the ICU. Subjects that are admitted and discharged in the same 24 hour period will be recorded as a LOS of 1 day, as will subjects discharged in the ensuing 24 hour period. LOS’s greater than 10 days will be truncated to 10 days.

Secondary Measures

  • Change in FEV1% Predicted
    • Time Frame: Measured at Baseline and Day 30
    • Change in Post-bronchodilator FEV1% predicted comparing data at 30 day visit with baseline.
  • Change in FEV1/FEV6 Levels
    • Time Frame: from baseline to day of discharge
    • Change in Post-bronchodilator FEV1/FEV6 ratio comparing data at discharge visit with baseline.
  • Treatment Failure
    • Time Frame: Baseline to day 30 visit
    • Treatment failure is defined as death, intubation, readmission to a hospital for COPD, urgent visit to an outpatient or ED provider for symptoms of COPD or intensification of therapy [including second course of antibiotics for COPD, and second course of systemic steroids for COPD]) in the first 30 days after randomization.
  • Health-related Quality of Life
    • Time Frame: Change from Baseline and 1 Month
    • St. George’s Respiratory Questionnaire – Total Score The SGRQ was asked with respect to the last one month as validated for acute exacerbations of COPD by Doll et al. Scale from 0 (no disability) to 100 (maximum disability). The SGRQ total score summarizes the impact of airway specific disease on overall health status. Scores range from zero (no impairment) to 100 (maximum impairment). Scores were calculated using the SGRQ scoring Algorithm.
  • Change in Urinary Leukotriene (LTE4) Levels
    • Time Frame: Baseline and 24 hours
    • Change in natural log-transformed LTE4 (ng/mg Cr.) from Baseline to 24 Hours
  • Change in Urinary Leukotriene (LTE4) Levels
    • Time Frame: Baseline and 72 hours later
    • Change in natural log-transformed LTE4 (ng/mg Cr.) from Baseline to 72 Hours

Participating in This Clinical Trial

Inclusion Criteria

  • Admitted to the hospital for a COPD exacerbation – FEV1 less than 60% of predicted level – At least 10 pack years of smoking Exclusion Criteria:

  • Any uncontrolled systemic disease – Known hypersensitivity to zileuton – Asthma – Lobar pneumonia or pulmonary edema – Interstitial lung disease – Medical condition that is likely to limit survival to less than 30 days at the time of study entry – History of liver disease – Current use of theophylline – Participation in another clinical trial in the COPD Clinical Research Network – Incarceration – Institutionalization – Pregnant – History of a suicide attempt – Prior inpatient admission for a psychiatric disorder – Bipolar disorder '

Gender Eligibility: All

Minimum Age: 45 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Minnesota
  • Collaborator
    • National Heart, Lung, and Blood Institute (NHLBI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Prescott Woodruff, MD, Study Chair, University of California at San Francisco

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.